Search
Equine Botulinum Neurotoxin G Immune FAB2
go.drugbank.com/drugs/DB13899ApprovedIt is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes G in adults and pediatric patients. … Equine Botulinum Neurotoxin G Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype G.
Equine Botulinum Neurotoxin D Immune FAB2
go.drugbank.com/drugs/DB13902ApprovedIt is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes D in adults and pediatric patients. … Equine Botulinum Neurotoxin D Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype D.
Taurochenodeoxycholic acid
go.drugbank.com/drugs/DB08833ExperimentalAs a medication, taurochenodeoxycholic acid reduces cholesterol formation in the liver, and is likely used as a choleretic to increase the volume of bile secretion from the liver and as a cholagogue to … Taurochenodeoxycholic acid is an experimental drug that is normally produced in the liver. Its physiologic function is to emulsify lipids such as cholesterol in the bile.
Categories: Compounds used in a research, industrial, or household settingLuspatercept
go.drugbank.com/drugs/DB12281ApprovedInvestigationalLuspatercept is a recombinant fusion protein comprised of a modified extracellular domain of activin receptor type IIB fused to the FC domain of human IgG1. … [A187829,L42455] It was first approved for use in the United States in November 2019 under the brand name Reblozyl® for the treatment of anemia in patients with beta thalassemia who require regular blood
Mefloquine
go.drugbank.com/drugs/DB00358ApprovedMalaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. … The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019.
Fenofibrate
go.drugbank.com/drugs/DB01039ApprovedInvestigationalFenofibrate is a fibric acid derivative like [clofibrate] and [gemfibrozil].[A185954] Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia. … [L8588,L8591] Fenofibrate was granted FDA approval on 31 December 1993.[L8585]
Products: Aa-feno-micro, Aa-feno-superTromethamine
go.drugbank.com/drugs/DB03754ApprovedInvestigationalIt is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used … as an alkalizer.
Categories: Compounds used in a research, industrial, or household settingEfmoroctocog alfa
go.drugbank.com/drugs/DB11607ApprovedInvestigationalFactor VIII is a blood coagulant factor involved in the intrinsic pathway to form fibrin, or a blood clot. … It is an antihemorrhagic agent used in replacement therapy for patients with haemophilia A (congenital factor VIII deficiency). It is suitable for all age groups.
Enprofylline
go.drugbank.com/drugs/DB00824ApprovedWithdrawnEnprofylline is a derivative of theophylline which shares bronchodilator properties. … Enprofylline is used in asthma, chronic obstructive pulmonary disease, and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy.
Synonyms: 3-n-propylxanthineVayarin
go.drugbank.com/drugs/DB09328ApprovedVayarin is a novel therapy for ADHD that appears to be effective in several studies [L1501, L1502, L1503]. … Vayarin is a prescription medical food for the clinical dietary management of certain lipid imbalances blamed to be associated with attention deficit hyperactivity disorder (ADHD) in children.